Live News ›
›
HomeNewsCorporate NewsPremiumStocks

Granules India: Emkay Sets ₹800 Target Amid USFDA Regulatory Concerns

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Granules India: Emkay Sets ₹800 Target Amid USFDA Regulatory Concerns
Overview

Emkay Global Financial launched coverage on Granules India with a BUY rating and a ₹800 target price, forecasting a ~20% EPS growth rate through FY28. Key catalysts include expansion in US controlled substances and shifts to higher-margin segments. However, the company's history of USFDA regulatory findings, especially at the Gagillapur facility, alongside a P/E ratio higher than some peers but below specialized API players, means investors must look closely at its valuation sustainability and compliance risks.

Emkay Initiates Coverage with High Target, Citing Growth Drivers

Emkay Global Financial has initiated coverage on Granules India, setting a target price of ₹800 and projecting a compound annual growth rate (CAGR) of around 20% for earnings per share (EPS) through FY28. The brokerage highlights key growth drivers, including expansion in U.S. controlled substances and strategic shifts to higher-margin segments. The company anticipates its controlled substances segment to account for nearly 30% of consolidated sales by FY26, acting as a significant multi-year growth catalyst. Granules India is also transitioning its business model—moving from API/PFI to Finished Dosage Forms (FDF), from B2B to B2C, and from legacy to complex generics—all aimed at boosting profitability. Potential clearance of the Gagillapur facility in FY27, growth in its peptide CDMO business (Senn), and a recent capital raise for potential acquisitions further contribute to the positive outlook.

Valuation Snapshot: Target Price vs. Peers

Emkay's ₹800 target implies a potential ~30% upside from current levels, positioning Granules India as a high-conviction small-cap pick. Trading around ₹620-₹635, the company's trailing 12-month P/E ratio stands at approximately 27-28x. This valuation is higher than peers like Dr. Reddy's Laboratories (18.3x P/E) and Aurobindo Pharma (21.5x P/E) but lower than specialized API manufacturers such as Divi's Laboratories (63.7x P/E) and Laurus Labs (63.6x P/E). Granules India's P/E is slightly below the broader Nifty Pharma Index (33.3x), suggesting its valuation reflects substantial growth expectations. While most analysts have consensus targets around ₹650-₹660, Emkay's ₹800 target presents a more ambitious projection. The stock has shown resilience, climbing about 27.31% over the past year. This performance occurs as the Indian pharmaceutical sector is forecast to grow 7-9% in FY26, driven by domestic demand and European exports, while the U.S. market faces pricing and regulatory challenges.

Regulatory Hurdles: USFDA Concerns Persist

Despite the positive analyst sentiment, Granules India's operational history involves significant risks, particularly concerning U.S. Food and Drug Administration (USFDA) oversight. The Gagillapur facility faced USFDA scrutiny during an August 2024 inspection, resulting in a warning letter that cited six major violations. These included issues like unclean equipment, unresolved production problems, inadequate facility maintenance, and observations of bird droppings near air units. Although the company is undertaking remediation, past regulatory issues at this facility have historically delayed product approvals. More recently, a Telangana plant operated by Granules Life Sciences received a Voluntary Action Indicated (VAI) classification from the USFDA following a December 2025 inspection. A VAI status means the FDA found compliance issues that require voluntary correction, even though no immediate regulatory action was recommended. This finding echoes concerns from 2022 regarding Intas Pharmaceuticals' facility, which also faced similar FDA observations, including data integrity issues and contamination, ultimately leading to an Import Alert and Warning Letter. For Granules India, which depends heavily on regulated markets like the U.S., consistent regulatory compliance is crucial. The VAI status, combined with ongoing concerns from the Gagillapur facility, introduces uncertainty about future product approvals and operational continuity that the current valuation may not fully reflect.

The Path Forward: Strategy, Growth, and Risks

Looking ahead, Granules India's strategy centers on complex generics, finished dosage forms, and expanding its peptide CDMO capabilities, notably through acquisitions like Senn Chemicals. Analysts forecast revenue growth rates that are expected to surpass the broader Indian market, with strong EPS growth anticipated. The company's success will hinge on its ability to navigate current regulatory requirements and effectively utilize its expanded manufacturing capacity. Management expresses confidence in its initiatives and product pipeline to enhance profitability and operational efficiency. The recent capital infusion is also intended to support potential acquisitions, further diversifying the company's business and strengthening its market position. However, sustained investor attention will be critical to monitor the resolution of past regulatory findings and their impact on future market access and financial performance.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.